Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.114163
Revised: October 8, 2025
Accepted: December 3, 2025
Published online: February 15, 2026
Processing time: 143 Days and 14 Hours
This commentary critically appraises Chen et al, who delineate the nuclear factor kappa B (NF-κB)-microRNA-136 (miR-136)-programmed cell death protein 11 (PDCD11) axis in Helicobacter pylori (H. pylori)-associated gastric carcinogenesis and propose H. pylori-induced miR-136 as a potential biomarker for early gastric cancer (GC). The study’s major strength lies in its multi-level validation - clinical specimen analysis, in vitro assays, and in vivo models - which collectively support a model in which H. pylori activates NF-κB to upregulate miR-136, and miR-136 in turn suppresses PDCD11 to promote GC cell proliferation, migration, and tumorigenicity. These findings lend experimental weight to the inflammation → molecular alteration → carcinogenesis paradigm and identify a novel axis for early intervention. Nonetheless, important mechanistic and methodological gaps limit translational readiness. Mechanistically, the work does not dissect how specific H. pylori virulence factors trigger NF-κB activation, nor does it define the downstream effectors and signaling cascades through which PDCD11 loss drives malignant phenotypes. Furthermore, this study did not detect the apoptotic properties of the PDCD11 protein. The study also omits an analysis of why miR-136 function may vary across histological subtypes. At the methodological level, in vitro validation was confined to only two GC cell lines. It lacked models representing the early stages of gastric mucosal transformation, which hinders the study’s ability to unravel the temporal dynamics of miR-136 function and its subtype specificity. Additionally, the experimental result figures of this study contain several flaws in terms of labeling, completeness, and consistency, which may interfere with readers’ accurate understanding of the results. To advance clinical translation, future studies should clarify the precise molecular links between H. pylori components and NF-κB activation, elucidate the downstream pathways of PDCD11, and investigate the heterogeneity of miR-136 across different pathological subtypes. Furthermore, conducting robust validation in multicenter, larger-scale cohorts and establishing expanded cellular models that include gastric mucosal cells and subtype-representative cell lines will also be essential tasks. Despite these limitations, by identifying a targetable regulatory axis and providing directions for in-depth mechanistic and translational research on miR-136 as an early diagnostic and therapeutic target, this study still makes a meaningful contribution to research on H. pylori-associated GC.
Core Tip: This study identified microRNA-136 as a potential diagnostic biomarker and therapeutic target for early-stage gastric cancer, demonstrating its role in tumor growth and metastasis through in vitro and in vivo models. Targeting the nuclear factor kappa B/microRNA-136/programmed cell death protein 11 axis may offer new strategies for intervention.